- ￥6600
- Solarbio
- 北京
- IO1470
- 2025年07月23日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 技术资料
- 保存条件：
Powder: -20℃，2 years
- 保质期：
Powder: -20℃，2 years
- 英文名：
ODN 2216
- 库存：
现询
- 供应商：
北京索莱宝科技有限公司
- CAS号：
332437-00-0
- 规格：
1mg
| 基本信息 | |
| CAS | No.332437-00-0 |
| 英文名称 | ODN 2216 |
| 溶解性 | Soluble in --- |
| 纯度 | ≥97% |
| 外观(性状) | Solid |
| 储存条件 | Powder: -20℃，2 years |
| SMILES | CC1=CN(C(=O)NC1=O)C2CC(C(O2)COP(=O)(O)OC3CC(OC3COP(=O)(O)OC4CC(OC4COP(=O)(O)OC5CC(OC5COP(=O)(O)OC6CC(OC6COP(=O)(O)OC7CC(OC7COP(=O)(O)OC8CC(OC8COP(=O)(O)OC9CC(OC9COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)OC1CC(OC1COP(=O)(O)O)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C(N=CN=C21)N)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)N1C=NC2=C(N=CN=C21)N)N1C=C(C(=O)NC1=O)C)N1C=CC(=NC1=O)N)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(O)OCC1C(CC(O1)N1C=CC(=NC1=O)N)OP(=O)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)OP(=O)(O)OCC1C(CC(O1)N1C=NC2=C1N=C(NC2=O)N)O |
| InChIKey | OGIAAULPRXAQEV-UHFFFAOYSA-N |
| InChI | InChI=1S/C197H244N88O121P20/c1-68-29-269(196(305)264-165(68)287)117-13-74(95(372-117)36-353-416(326，327)396-78-16-120(272-54-221-134-149(202)217-52-219-151(134)272)376-98(78)39-356-418(330，331)398-81-20-124(277-59-226-139-156(277)242-184(207)255-171(139)293)379-101(81)42-358-411(316，317)390-73-12-116(268-8-5-112(200)237-195(268)304)371-94(73)35-352-415(324，325)395-77-15-119(271-53-220-133-148(201)216-51-218-150(133)271)375-97(77)38-355-419(332，333)399-84-23-127(280-62-229-142-159(280)245-187(210)258-174(142)296)382-104(84)45-362-423(340，341)403-88-27-131(284-66-233-146-163(284)249-191(214)262-178(146)300)386-108(88)49-366-426(346，347)405-87-26-130(283-65-232-145-162(283)248-190(213)261-177(145)299)385-107(87)48-364-422(338，339)401-83-22-126(279-61-228-141-158(279)244-186(209)257-173(141)295)381-103(83)44-360-414(322，323)393-76-17-121(374-91(76)32-348-407(307，308)309)274-56-223-136-153(274)239-181(204)252-168(136)290)391-412(318，319)350-33-92-71(10-114(369-92)266-6-3-110(198)235-193(266)302)388-409(312，313)357-41-100-80(19-123(378-100)276-58-225-138-155(276)241-183(206)254-170(138)292)397-417(328，329)354-37-96-75(14-118(373-96)270-30-69(2)166(288)265-197(270)306)392-413(320，321)351-34-93-72(11-115(370-93)267-7-4-111(199)236-194(267)303)389-410(314，315)359-43-102-82(21-125(380-102)278-60-227-140-157(278)243-185(208)256-172(140)294)400-421(336，337)363-47-106-86(25-129(384-106)282-64-231-144-161(282)247-189(212)260-176(144)298)404-425(344，345)367-50-109-89(28-132(387-109)285-67-234-147-164(285)250-192(215)263-179(147)301)406-424(342，343)365-46-105-85(24-128(383-105)281-63-230-143-160(281)246-188(211)259-175(143)297)402-420(334，335)361-40-99-79(18-122(377-99)275-57-224-137-154(275)240-182(205)253-169(137)291)394-408(310，311)349-31-90-70(286)9-113(368-90)273-55-222-135-152(273)238-180(203)251-167(135)289/h3-8，29-30，51-67，70-109，113-132，286H，9-28，31-50H2，1-2H3，(H，310，311)(H，312，313)(H，314，315)(H，316，317)(H，318，319)(H，320，321)(H，322，323)(H，324，325)(H，326，327)(H，328，329)(H，330，331)(H，332，333)(H，334，335)(H，336，337)(H，338，339)(H，340，341)(H，342，343)(H，344，345)(H，346，347)(H2，198，235，302)(H2，199，236，303)(H2，200，237，304)(H2，201，216，218)(H2，202，217，219)(H，264，287，305)(H，265，288，306)(H2，307，308，309)(H3，203，238，251，289)(H3，204，239，252，290)(H3，205，240，253，291)(H3，206，241，254，292)(H3，207，242，255，293)(H3，208，243，256，294)(H3，209，244，257，295)(H3，210，245，258，296)(H3，211，246，259，297)(H3，212，247，260，298)(H3，213，248，261，299)(H3，214，249，262，300)(H3，215，250，263，301) |
| PubChem CID | 49771845 |
| 靶点 | TLR9 |
| 通路 | Immunology & Inflammation |
| 背景说明 | ODN 2216 是一种 TLR9 (toll 样受体 9) 配体或激动剂。 |
| 生物活性 | ODN?2216 is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN?2216 induces high amounts of IFN-α and IFN-β. ODN 2216 induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC)， which is indirect and mediated by IFN-α/β. ODN 2216 can activate NK cells and promote IFN-γ production of TCR-triggered CD4+ T cells[1][2][3][4][5]. |
| In Vitro | Here we describe distinct CpG-containing oligonucleotide sequences which， in contrast to previously described CpG ODN， induced high amounts of IFN-alpha and IFN-beta in peripheral blood mononuclear cells (PBMC). Intracellular staining for IFN-alpha revealed that within PBMC CpG ODN-induced IFN-alpha is produced exclusively by PDC. Unlike IFN-alpha， TNF-alpha is up-regulated in PDC by all CpG ODN tested. Purified PDC responded to CpG ODN， demonstrating direct activation of PDC by CpG ODN. The most active sequence induced the production of up to 5 pg IFN-alpha per single PDC， resulting in more than 400 ng/ml IFN-alpha in the supernatant of PBMC enriched for PDC.The potency of CpG ODN to stimulate IFN-alpha correlated with their ability to stimulate NK cell lytic activity， while purified NK cells did not respond to CpG ODN. IFNgamma production in PBMC was dependent on CpG ODN-induced IFN-alpha/beta as demonstrated by IFN-alpha/beta blocking Antibodies. IFN-alpha-inducing CpG ODN strongly supported IFN-gamma production of TCR-triggered CD4 T cells but were less active than Other CpG ODN in stimulating B cells.[2]。Apoptosis Analysis[2]：Cell Line:Thymic DC， pDC；Concentration:2 μM；Incubation Time:15 h；Result:Significantly decreased apoptosis of thymic DC (23.1 ± 0.9%)， and naturally induced apoptosis of thymic pDC was not decreased (72.8 ± 2.9%). |
| 细胞实验 | In this study， however， we unexpectedly found that two types of CpG - based tumor peptide vaccine treatments consistently negated the antitumor activity of a selective BRAF inhibitor in tumors with BRAF mutation rather than showing a synergistic antitumor effect.Our further studies demonstrated that CpG alone was sufficient to dampen BRAF inhibitor - induced antitumor responses， suggesting that the impaired antitumor activity of the BRAF inhibitor observed in mice receiving CpG - based peptide vaccine is mainly dependent upon the use of CpG.Mechanistically， CpG increased the number of circulating B cells， which produced elevated amounts of tumor necrosis factor - α (TNFα) that contributed to the increased tumor resistance to BRAF inhibitors.More importantly， B - cell depletion or TNFα neutralization can restore the antitumor effect of BRAF inhibition in mice receiving CpG treatment， indicating that TNFα - secreting B cells play an indispensable role in BRAF inhibitor resistance induced by CpG.[3] |
| 数据来源文献 | [1]. Krug A， et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol. 2001 Jul;31(7):2154-63. [2]. Okada T， et al. Murine thymic plasmacytoid dendritic cells. Eur J Immunol. 2003 Apr;33(4):1012-9. [3]. Huang L， et al. CpG-based immunotherapy impairs antitumor activity of BRAF inhibitors in a B-cell-dependent manner. Oncogene. 2017 Jul 13;36(28):4081-4086. [4]. He Y， et al. Hepatic mitochondrial DNA/Toll-like receptor 9/MicroRNA-223 forms a negative feedback loop to limit neutrophil overactivation and acetaminophen hepatotoxicity in mice. Hepatology. 2017 Jul;66(1):220-234. [5]. Li Y， et al. A novel antagonist of TLR9 blocking all classes of immunostimulatory CpG-ODNs. Vaccine. 2011 Mar 3;29(11):2193-8. |
| 单位 | 瓶 |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
技术资料暂无技术资料 索取技术资料
IO1470 ODN 2216 免疫学/炎症 索莱宝
￥6600
